Insys Therapeutics, Inc. Form 4

November 18, 2015

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Check this box if no longer

subject to Section 16. Form 4 or

Form 5 obligations

may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES** 

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \* JOHN N KAPOOR TRUST DATED **SEPTEMBER 20 1989** 

(Last)

(First)

(Middle)

C/O INSYS THERAPEUTICS,

INC., 444 SOUTH ELLIS STREET

(Street)

CHANDLER, AZ 85224

Filed(Month/Day/Year)

2. Issuer Name and Ticker or Trading

Symbol

Insys Therapeutics, Inc. [INSY]

3. Date of Earliest Transaction (Month/Day/Year) 11/17/2015

4. If Amendment, Date Original

**OMB APPROVAL** 

**OMB** Number:

3235-0287

Expires:

January 31, 2005

Estimated average burden hours per

response...

0.5

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

\_X\_\_ 10% Owner Director \_ Other (specify Officer (give title

below)

6. Individual or Joint/Group Filing(Check

Applicable Line)

Form filed by One Reporting Person X Form filed by More than One Reporting

(City)	(State)	(Zip) Tab	ole I - Non-	Derivative	e Secu	rities Ac	quired, Disposed	of, or Benefic	cially Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code (Instr. 3, 4 and 5) Year) (Instr. 8)		d of (D)	5. Amount of 6. Securities Ownership Beneficially Form: Owned Direct (D) Following or Indirect Reported (I)		7. Nature of Indirect Beneficial Ownership (Instr. 4)	
			Code V	Amount	(A) or (D)	Price	Transaction(s) (Instr. 4) (Instr. 3 and 4)		
Common Stock	11/17/2015		P	4,250	A	29.38 (1)	42,373,860	I	By Trust (2)
Common Stock	11/17/2015		P	750	A	\$ 30.17 (3)	42,374,610	I	By Trust (2)
Common Stock							31,982	D	
Common Stock							56,288	I	By Partnership

### Edgar Filing: Insys Therapeutics, Inc. - Form 4

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

> 9. Nu Deriv Secur Bene Own Follo Repo Trans (Instr

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5.	<ol><li>Date Exer</li></ol>	cisable and	7. Title	and	8. Price of
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transac	ctionNumber	Expiration D	ate	Amoun	t of	Derivative
Security	or Exercise		any	Code	of	(Month/Day	/Year)	Underly	ying	Security
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8	<ol><li>B) Derivati</li></ol>	ve		Securiti	ies	(Instr. 5)
	Derivative				Securiti	es		(Instr. 3	3 and 4)	
	Security				Acquire	d				
					(A) or					
					Dispose	d				
					of (D)					
					(Instr. 3	,				
					4, and 5	)				
								,	Amount	
									or	
						Date	Expiration		Number	
					Exercisable Date		Date		of	
				Code	V (A) (D	)			Shares	

## **Reporting Owners**

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
JOHN N KAPOOR TRUST DATED SEPTEMBER 20 1989 C/O INSYS THERAPEUTICS, INC. 444 SOUTH ELLIS STREET CHANDLER, AZ 85224		X				
KAPOOR JOHN N 444 SOUTH ELLIS STREET CHANDLER, AZ 85224	X	X	President & CEO			

# **Signatures**

/s/ John N. Kapoor	11/18/2015			
**Signature of Reporting Person	Date			
John N. Kapoor	11/18/2015			
**Signature of Reporting Person	Date			

Reporting Owners 2

# **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$28.94 to \$29.87, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the
- Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.
- (2) By The John N. Kapoor Trust dated September 20, 1989.
  - The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$30.11 to \$30.21, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the
- Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.
- (4) By EJ Financial/NEO Management, L.P. of which the reporting person is Managing General Partner.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.